NHS-Galleri trial participant testimonial: Robert, Cancer Signal Detected

Robert, a carpenter, enrolled in the NHS-Galleri trial at the age of 55. The NHS-Galleri trial is a research study in England that is evaluating whether annual screening with the Galleri multi-cancer early detection (MCED) blood test can help the NHS to detect cancer early when used alongside existing cancer screening programmes. Watch Robert’s story of how he was diagnosed with Stage I head and neck cancer following a Cancer Signal Detected result from the Galleri test. His cancer was found at an early stage, when it was barely visible on scans. Learn more: https://grail.com https://galleri.com Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result, which includes a predicted Cancer Signal Origin. After diagnostic evaluation, around 62% of these people are expected to have a confirmed cancer diagnosis. The overall sensitivity in participants with head and neck cancer in a clinical study was 85.7% (63.2% for stage I, 82.4% stage II, 84.2% stage III, 96.0% stage IV). Rx only. See Important Safety Information: https://www.galleri.com/safety